EA019517B1 - Антитела к tyrp1 и их применение - Google Patents

Антитела к tyrp1 и их применение Download PDF

Info

Publication number
EA019517B1
EA019517B1 EA201071068A EA201071068A EA019517B1 EA 019517 B1 EA019517 B1 EA 019517B1 EA 201071068 A EA201071068 A EA 201071068A EA 201071068 A EA201071068 A EA 201071068A EA 019517 B1 EA019517 B1 EA 019517B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
antibodies
fragment
present
human
Prior art date
Application number
EA201071068A
Other languages
English (en)
Russian (ru)
Other versions
EA201071068A1 (ru
Inventor
Сяоцян Кан
Пол Дж. Балдерес
Original Assignee
Имклоун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA019517(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Имклоун Элэлси filed Critical Имклоун Элэлси
Publication of EA201071068A1 publication Critical patent/EA201071068A1/ru
Publication of EA019517B1 publication Critical patent/EA019517B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201071068A 2008-03-12 2009-03-11 Антитела к tyrp1 и их применение EA019517B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6919908P 2008-03-12 2008-03-12
PCT/US2009/036739 WO2009114585A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Publications (2)

Publication Number Publication Date
EA201071068A1 EA201071068A1 (ru) 2011-04-29
EA019517B1 true EA019517B1 (ru) 2014-04-30

Family

ID=40790741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071068A EA019517B1 (ru) 2008-03-12 2009-03-11 Антитела к tyrp1 и их применение

Country Status (19)

Country Link
US (1) US7951370B2 (https=)
EP (1) EP2268672A1 (https=)
JP (1) JP2011516041A (https=)
KR (1) KR101203777B1 (https=)
CN (1) CN101970500B (https=)
AR (1) AR070821A1 (https=)
AU (1) AU2009222998B2 (https=)
BR (1) BRPI0909633A2 (https=)
CA (1) CA2718289A1 (https=)
CL (1) CL2009000567A1 (https=)
EA (1) EA019517B1 (https=)
IL (1) IL207581A0 (https=)
MX (1) MX2010010021A (https=)
NZ (1) NZ587305A (https=)
PE (1) PE20091679A1 (https=)
TW (1) TWI384997B (https=)
UA (1) UA99339C2 (https=)
WO (1) WO2009114585A1 (https=)
ZA (1) ZA201006099B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
SG11201606439VA (en) 2014-02-07 2016-09-29 Dong Wha Pharm Co Ltd Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
DK3233907T3 (da) 2014-12-19 2021-06-07 Genmab As Bispecifikke heterodimeriske proteiner hos gnavere
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
AU2017418590A1 (en) * 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
PL3856775T3 (pl) 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
US12371507B2 (en) 2018-11-09 2025-07-29 Beth Israel Deaconess Medical Center CDCP1 antibodies and antibody drug conjugates
SG10202105788SA (en) * 2018-12-21 2021-06-29 Hoffmann La Roche Antibodies binding to cd3
AU2020343025A1 (en) * 2019-09-06 2022-04-07 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
CN115515976A (zh) * 2020-03-19 2022-12-23 帝国理工学院创新有限公司 冠状病毒抗体
JP2024543257A (ja) * 2021-11-26 2024-11-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798790A (en) * 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
IE910820A1 (en) 1990-03-22 1991-09-25 Sloan Kettering Inst Cancer Gp75 as a tumor vaccine for melanoma
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
AU6171196A (en) 1995-06-07 1996-12-30 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDERSON C.M. ET AL.: "SYSTEMIC TREATMENTS FOR ADVANCED CUTANEOUS MELANOMA". ONCOLOGY, S. KARGER, BASEL, CH, vol. 9, no. 11, 1 November, 1995 (1995-11-01), pages 1149-1158, XP000612582, ISSN: 0030-2414, the whole document *
BEVAART LISETTE ET AL.: "The high-affinity IgG receptor, Fc gamma RI, plays a central role in antibody therapy of experimental melanoma". CANCER RESEARCH, vol. 66, no. 3, February 2006 (2006-02), pages 1261-1264, XP002534925, ISSN: 0008-5472, the whole document *
O'DAY STEVEN J. ET AL.: "Metastatic melanoma: chemotherapy to biochemotherapy". CANCER CONTROL: JOURNAL OF THE MOFFITT CANCER CENTER 2002 JAN-FEB, vol. 9, no. 1, January 2002 (2002-01), pages 31-38, XP002535042, ISSN: 1073-2748, the whole document *
PATEL DIPA ET AL.: "Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1". HUMAN ANTIBODIES, AMSTERDAM, NL, vol. 16, no. 3-4, 1 January, 2007 (2007-01-01), pages 127-136, XP009119042, ISSN: 1093-2607, the whole document *

Also Published As

Publication number Publication date
WO2009114585A1 (en) 2009-09-17
AR070821A1 (es) 2010-05-05
EP2268672A1 (en) 2011-01-05
AU2009222998B2 (en) 2013-05-23
US7951370B2 (en) 2011-05-31
BRPI0909633A2 (pt) 2015-09-22
JP2011516041A (ja) 2011-05-26
KR101203777B1 (ko) 2012-11-21
AU2009222998A1 (en) 2009-09-17
CL2009000567A1 (es) 2010-02-26
PE20091679A1 (es) 2009-11-04
MX2010010021A (es) 2011-02-15
EA201071068A1 (ru) 2011-04-29
UA99339C2 (ru) 2012-08-10
IL207581A0 (en) 2010-12-30
TW200944232A (en) 2009-11-01
CN101970500B (zh) 2013-08-14
CA2718289A1 (en) 2009-09-17
ZA201006099B (en) 2012-01-25
KR20100113631A (ko) 2010-10-21
US20090232823A1 (en) 2009-09-17
CN101970500A (zh) 2011-02-09
NZ587305A (en) 2012-05-25
TWI384997B (zh) 2013-02-11

Similar Documents

Publication Publication Date Title
EA019517B1 (ru) Антитела к tyrp1 и их применение
JP3066983B2 (ja) 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体
US9951143B2 (en) Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
EP4332117A1 (en) Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal user thereof
EP4094779A1 (en) Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
RU2568051C2 (ru) АНТИТЕЛА К ErbB3
TWI402078B (zh) 抗ｃｓｆ－１ｒ抗體
JP4854912B2 (ja) 癌に対する抗体
BR112021001201A2 (pt) anticorpo anti-tigit e uso do mesmo
JP2019501973A (ja) スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
EP4417622A1 (en) Anti-cd26 antibody and use thereof
PT1360208E (pt) Anticorpos anti cancerígenos individualizados
EP4549469A1 (en) Antibody targeting melanoma cells
CA2494319A1 (en) Use of antibodies against a tumor-associated antigen
JP2024167313A (ja) 腫瘍治療薬及びその応用
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
AU2024319528A1 (en) Anti-psma antibody-drug conjugate and pharmaceutical use thereof
TW202304983A (zh) 抗ｈｅｒ３抗體和抗ｈｅｒ３抗體藥物偶聯物及其醫藥用途
HK1168109A (en) Anti-axl antibody
JP2017526369A (ja) 治療用および診断用の抗ｌｏｘｌ４抗体
EP1757305A2 (en) Individualized anti-cancer antibodies
AU3135300A (en) Anti-p53 antibodies

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU